A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities

Aberrant Wnt signaling activation is frequently observed in many cancers. The mutation acquisition of Wnt signaling leads to tumorigenesis, whereas the inhibition of Wnt signaling robustly suppresses tumor development in various in vivo models. Based on the excellent preclinical effect of targeting...

Full description

Bibliographic Details
Main Authors: Woo-Jung Park, Moon Jong Kim
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/12/8/1110
_version_ 1797606012576858112
author Woo-Jung Park
Moon Jong Kim
author_facet Woo-Jung Park
Moon Jong Kim
author_sort Woo-Jung Park
collection DOAJ
description Aberrant Wnt signaling activation is frequently observed in many cancers. The mutation acquisition of Wnt signaling leads to tumorigenesis, whereas the inhibition of Wnt signaling robustly suppresses tumor development in various in vivo models. Based on the excellent preclinical effect of targeting Wnt signaling, over the past 40 years, numerous Wnt-targeted therapies have been investigated for cancer treatment. However, Wnt signaling-targeting drugs are still not clinically available. A major obstacle to Wnt targeting is the concomitant side effects during treatment due to the pleiotropic role of Wnt signaling in development, tissue homeostasis, and stem cells. Additionally, the complexity of the Wnt signaling cascades across different cancer contexts hinders the development of optimized targeted therapies. Although the therapeutic targeting of Wnt signaling remains challenging, alternative strategies have been continuously developed alongside technological advances. In this review, we give an overview of current Wnt targeting strategies and discuss recent promising trials that have the potential to be clinically realized based on their mechanism of action. Furthermore, we highlight new waves of Wnt targeting that combine recently developed technologies such as PROTAC/molecular glue, antibody–drug conjugates (ADC), and anti-sense oligonucleotides (ASO), which may provide us with new opportunities to target ‘undruggable’ Wnt signaling.
first_indexed 2024-03-11T05:09:20Z
format Article
id doaj.art-ac02d529c6a2402f8dc65ce9a83f6828
institution Directory Open Access Journal
issn 2073-4409
language English
last_indexed 2024-03-11T05:09:20Z
publishDate 2023-04-01
publisher MDPI AG
record_format Article
series Cells
spelling doaj.art-ac02d529c6a2402f8dc65ce9a83f68282023-11-17T18:42:41ZengMDPI AGCells2073-44092023-04-01128111010.3390/cells12081110A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and OpportunitiesWoo-Jung Park0Moon Jong Kim1Department of Life Science, Gachon University, Seongnam 13120, Republic of KoreaDepartment of Life Science, Gachon University, Seongnam 13120, Republic of KoreaAberrant Wnt signaling activation is frequently observed in many cancers. The mutation acquisition of Wnt signaling leads to tumorigenesis, whereas the inhibition of Wnt signaling robustly suppresses tumor development in various in vivo models. Based on the excellent preclinical effect of targeting Wnt signaling, over the past 40 years, numerous Wnt-targeted therapies have been investigated for cancer treatment. However, Wnt signaling-targeting drugs are still not clinically available. A major obstacle to Wnt targeting is the concomitant side effects during treatment due to the pleiotropic role of Wnt signaling in development, tissue homeostasis, and stem cells. Additionally, the complexity of the Wnt signaling cascades across different cancer contexts hinders the development of optimized targeted therapies. Although the therapeutic targeting of Wnt signaling remains challenging, alternative strategies have been continuously developed alongside technological advances. In this review, we give an overview of current Wnt targeting strategies and discuss recent promising trials that have the potential to be clinically realized based on their mechanism of action. Furthermore, we highlight new waves of Wnt targeting that combine recently developed technologies such as PROTAC/molecular glue, antibody–drug conjugates (ADC), and anti-sense oligonucleotides (ASO), which may provide us with new opportunities to target ‘undruggable’ Wnt signaling.https://www.mdpi.com/2073-4409/12/8/1110Wnt signalingβ-catenintargeted cancer therapyPROTACantibody–drug conjugate (ADC)anti-sense oligonucleotide (ASO)
spellingShingle Woo-Jung Park
Moon Jong Kim
A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
Cells
Wnt signaling
β-catenin
targeted cancer therapy
PROTAC
antibody–drug conjugate (ADC)
anti-sense oligonucleotide (ASO)
title A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
title_full A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
title_fullStr A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
title_full_unstemmed A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
title_short A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
title_sort new wave of targeting undruggable wnt signaling for cancer therapy challenges and opportunities
topic Wnt signaling
β-catenin
targeted cancer therapy
PROTAC
antibody–drug conjugate (ADC)
anti-sense oligonucleotide (ASO)
url https://www.mdpi.com/2073-4409/12/8/1110
work_keys_str_mv AT woojungpark anewwaveoftargetingundruggablewntsignalingforcancertherapychallengesandopportunities
AT moonjongkim anewwaveoftargetingundruggablewntsignalingforcancertherapychallengesandopportunities
AT woojungpark newwaveoftargetingundruggablewntsignalingforcancertherapychallengesandopportunities
AT moonjongkim newwaveoftargetingundruggablewntsignalingforcancertherapychallengesandopportunities